PainReform - PRFX Total Company Value-to-Revenue Ratio

The historical EV/Sales level for PainReform Ltd. (PRFX) demonstrates a trend comparable to the readiness of production capacities for mass output. The current level is approximately -300333.33, supported by established relationships with research centers and distributors. Valuation stability is ensured by the proficient management of global logistics chains, which minimize supply disruptions and maintain high sales profitability.
PainReform - analytical breakdowns and key metrics (PRFX)

This metric is calculated as the ratio of the total enterprise value, including market capitalization and net debt, to annual revenue, allowing for an assessment of the real value of assets without the influence of leverage. For PainReform Ltd. (PRFX), the enterprise value-to-sales multiple reflects market expectations for the commercialization of long-term pain relief drugs, helping investors determine the degree of business overvaluation relative to current revenue generation rates.